Product imageResearch use only

CAT. NO. DC67295Featured

Lipid MK16

Pack size & price

USD

Add the cited formulation componentsSelected Lipid MK16 pack + every supporting component at 100 mg each+US$450 / set

Supporting components

DOPE DC33634 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2k DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$700

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

MK16 is an ionizable lipid studied in blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery. Published studies report expression in mouse brain cells, ex vivo adult human cortical tissue and an orthotopic glioblastoma model. Performance depends on the full formulation, cargo, dose and model.

Open full Formulation & Performance →

Literature evidence · DC67295

Formulation & Performance

Mouse brain delivery, human tissue expression and tumour-model outcomes are separated below, with the corresponding formulation and safety observations.

The results below describe the cited research formulations. Product specifications and commercial pack options are shown in the Specifications and ordering sections.

Formulation components and molecular-weight conversion

Component	DC Chemicals product	Molecular weight	Molar ratio	Mass at 1 µmol total lipid (mg)
MK16	DC67295	997.84	60	0.457900
DOPE	DC33634	744.03	30	0.170714
Cholesterol	DCD-041	386.65	40	0.118287
DMG-PEG2000	DC40169	2507	0.75	0.014380

MK16/DOPE/cholesterol/DMG-PEG2000 = 60:30:40:0.75 relative molar parts, not mol%. The parts sum to 130.75 and are normalized only for the calculated masses. MK16:mRNA = 12.5:1 by weight; N/P was not disclosed. Source: formulation selection in the main text and Supplementary Fig. 6a.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

Total lipid (µmol)

Component	Mass (mg)	Mass %
MK16	—	—
DOPE	—	—
Cholesterol	—	—
DMG-PEG2000	—	—

Particle properties and loading

Measurement	Reported result	Source / interpretation
Particle diameter	137.0 ± 4.1 nm	Supplementary Fig. 9a; mean ± SD, n = 3 biological samples
mRNA encapsulation efficiency	84.8 ± 1.5%	Supplementary Fig. 9b; mean ± SD, n = 3
Apparent LNP pKa	6.86	Supplementary Fig. 6d; TNS assay, a formulation property
PDI / zeta potential	Shown graphically; positive zeta potential	Supplementary Figs. 6 and 9. Exact values are not newly inferred from bar heights.

Brain expression after intravenous mRNA delivery

Model / endpoint	Dose / assessment	Result and comparator
Mouse brain FLuc expression	0.5 mg/kg mRNA; 6 h	8.3-fold above MC3 and 1.7-fold above MK6E in the tested formulations (Fig. 3d,e).
Additional FLuc benchmarks	Same brain-expression study context	7.4-fold above ALC-0315 and 6.5-fold above SM-102 (Supplementary Fig. 8).
Neurons / astrocytes, GFP-positive	0.5 mg/kg IV; 12 h	4.64 ± 1.00% / 6.63 ± 0.62% (Fig. 3f,g).
Brain endothelial cells / microglia, GFP-positive	0.5 mg/kg IV; 12 h	5.62 ± 0.78% / 1.68 ± 0.15% (Fig. 3f,g and Supplementary Fig. 11).
Higher-dose GFP expression	1 mg/kg IV; 12 h	Neurons 7.36 ± 0.78%; astrocytes 9.71 ± 0.70%; endothelial cells 9.18 ± 0.80%; microglia 2.85 ± 0.44%.

GFP values are percentages of the specified cell population (mean ± SD), not percentages of injected dose. FLuc differences compare complete LNP formulations.

Functional and disease-model evidence

Experiment	Evidence	Interpretation
Cre reporter mice	Brain tdTomato activation assessed 5 days after dosing; Fig. 4	Cre-mediated recombination establishes functional delivery; it is not a measurement of CRISPR editing efficiency.
Ex vivo human cortical tissue	Two adult donors; ΔFOSB expression in neurons and astrocytes; Fig. 5d,e	Excised tissue evidence does not demonstrate BBB crossing in living humans.
Orthotopic U-118MG glioblastoma	Pten mRNA, 1 mg/kg IV on days 10, 13 and 16; 70% of treated mice survived beyond 120 days; Fig. 6	Immunodeficient mouse model; comparator arms included PBS and control mRNA LNPs. This is not a clinical survival estimate.

Cell compatibility and tolerability

Setting	Observed result	Scope
N2a and bEnd.3 cells	Higher expression than the MC3 formulation; no significant viability difference from PBS at the tested conditions	Supplementary Fig. 9d,e; n = 3.
Mouse acute systemic evaluation	At 1 mg/kg mRNA, most measured cytokines returned toward baseline by 24–48 h; no obvious major-organ histological injury or abnormal liver/kidney markers reported	Supplementary Figs. 14–17; applies to the tested formulation, dose and observation windows.
Repeated dosing	The study also reports repeat-dose assessments	These experiments do not establish chronic or human safety.

Original study figures

Brain expression, functional delivery and tumour studies: Figures 3–6 — Original source figures.

Supplementary Figures 6, 8, 9 and 14–17 — Original source figures.

References and source locations

CAS No.	Not available
Chemical Name	Lipid MK16
Synonyms	Lipid-MK16, MK 16, MK-16, MK16 BL
SMILES	CC(OCCCCCC)OCCCCCCN(CCCCCCOC(C)OCCCCCC)CCCCCCNC(CC[C@H]1CC[C@@](C2=CC(F)=CC=C2F)(S(C3=CC=C(Cl)C=C3)(=O)=O)CC1)=O
Formula	C55H91ClF2N2O7S
M.Wt	997.84
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Wang C, Xue Y, Markovic T, et al. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nature Materials 24, 1653–1663 (2025). DOI: 10.1038/s41563-024-02114-5. Author manuscript, Figures 3–6 and associated Supplementary Information.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	10.0216 mL	2.0043 mL	1.0022 mL
25 mg	25.0541 mL	5.0108 mL	2.5054 mL
50 mg	50.1082 mL	10.0216 mL	5.0108 mL
100 mg	100.2165 mL	20.0433 mL	10.0216 mL
250 mg	250.5412 mL	50.1082 mL	25.0541 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

Lipid MK16

Pack size & price

Description & Application

Recommended Products

Lipid F10T5

C14-306

Lipid P3B

Lilly lipid 51

Lipid TD5

Lipid S4

Lipid CA2d

C6O2B2

Lipid 8

C12-4 (Lipid A-4,Lipid F3,C12-494)